Privia Health Group, Inc. files SEC reports that document its physician enablement business, operating results, governance and public-company capital structure. Its 8-K reports commonly furnish quarterly and annual financial releases, including revenue, care margin, platform contribution, adjusted EBITDA, guidance, value-based risk arrangements and provider-network growth.
Proxy and other material-event filings cover board and committee governance, shareholder voting matters, material agreements, risk factors, regulatory disclosures and other updates tied to a Delaware corporation listed on Nasdaq under PRVA.
Parth Mehrotra submitted a Form 144 notice regarding proposed sales of Common Stock. The filing lists 15,647 shares tied to restricted stock vesting dated 05/09/2026 and reports multiple reported dispositions in March–May 2026 totaling several transactions.
The record lists broker Fidelity Brokerage Services LLC and shows individual past sales on 03/06/2026, 03/09/2026, 03/10/2026, 03/12/2026, 03/13/2026, 03/16/2026, and 05/11/2026 with per‑trade share counts and proceeds reported in the filing.
Parth Mehrotra reported proposed sales of Common Stock of PRVA via Form 144. The notice lists restricted stock vesting entries of 30,538 shares on 03/11/2026, 30,072 shares on 03/12/2026, and 30,793 shares on 03/13/2026. The filing also records open-market dispositions during March: 21,440 shares on 03/06/2026 for $496,357.44, 41,999 shares on 03/09/2026 for $960,197.55, 21,097 shares on 03/10/2026 for $479,144.34, 26,763 shares on 03/12/2026 for $586,096.32, 27,229 shares on 03/13/2026 for $586,096.06, and 26,509 shares on 03/16/2026 for $586,108.69.
Affiliate filed a Form 144 reporting a proposed sale of 3,385 shares. The filing lists the securities to be sold as 3,385 shares tied to restricted stock vesting dated 05/08/2026. The excerpt also itemizes multiple past sales by David Mountcastle on various dates in 2026.
PRVA reported a Form 144 notice for the proposed sale of 14,036 shares of Common Stock. The filing lists the sale method as Restricted Stock Vesting and identifies the issuer as the seller on 05/08/2026. The filing also discloses multiple completed Common stock sales by Parth Mehrotra in March 2026, with individual transactions and gross proceeds reported for each date.
Privia Health Group, Inc. reported strong growth for the three months ended March 31, 2026, with revenue rising to $603.8 million from $480.1 million, driven mainly by higher fee-for-service patient care and value-based care revenue.
Care Margin increased to $128.7 million, Platform Contribution to $67.0 million, and Adjusted EBITDA to $36.7 million, showing improved operating leverage. Net income attributable to Privia Health declined to $3.1 million from $4.2 million as a higher effective tax rate and increased stock-based compensation offset operating gains.
Privia Health Group, Inc. reported strong growth for the first quarter ended March 31, 2026. Total revenue reached $603.8 million, up 25.8% from $480.1 million, while gross profit rose to $125.6 million, a 21.2% increase. Operating income improved to $7.4 million, up 42.2%.
GAAP net income attributable to Privia declined to $3.1 million from $4.2 million, and diluted EPS slipped to $0.02 from $0.03, reflecting higher non-cash stock compensation of $21.9 million. Non-GAAP adjusted net income increased to $24.3 million from $19.9 million, with adjusted diluted EPS rising to $0.19 from $0.16.
Key operating metrics were solid: implemented providers grew to 5,535 (up 13.6%), Attributed Lives to 1,606,000 (up 26.5%), and Practice Collections to $914.8 million (up 14.6%). Adjusted EBITDA increased to $36.7 million, up 36.3%, with margin expanding to 28.5% of Care Margin.
Cash flow from operations was a use of $49.5 million, and cash and cash equivalents ended the quarter at $419.5 million. For full-year 2026, Privia reiterated guidance for revenue, Adjusted EBITDA and other metrics, and raised its Attributed Lives outlook to 1,600,000–1,625,000, expecting about 80% of Adjusted EBITDA to convert to free cash flow.
Privia Health Group EVP & CFO David Mountcastle reported an exercise-and-sale of company stock. On May 1 and May 4, 2026, he exercised a total of 8,385 stock options for common shares at an exercise price of $2.00 per share and sold the same 8,385 shares in open-market transactions around $25 per share, according to the Form 4.
The sales were executed under a previously adopted Rule 10b5-1 trading plan, indicating they were pre-planned. After these transactions, Mountcastle directly owns 214,847 common shares and has indirect ownership of 8,695 shares held by his spouse, reflecting that he retains a substantial equity stake in Privia Health Group.
Privia Health Group, Inc. director Matthew Shawn Morris reported option exercises paired with open-market sales of common stock. On May 1 and May 4, 2026, he exercised stock options covering a total of 18,113 shares at $2.00 per share and sold the same number of shares in open-market trades at weighted-average prices of about $24.99 and $24.96 per share under a Rule 10b5-1 trading plan. Following these transactions, he directly holds 68,188 common shares, plus indirect holdings of 11,998 shares held by a trust and 12,487 shares held by Emerald Family, LLC, and retains stock options covering 3,674,201 underlying shares expiring in 2033.
PRVA reported proposed insider sales via a Form 144 notice. The filing lists multiple planned cash sales of Common shares, with option-derived share amounts shown for grants dated 08/28/2018, 03/20/2019, 12/04/2019, and 09/08/2020. The filing also lists actual open-market dispositions by a reported holder on specific dates in 2026.
PRVA reported insider sell transactions via Form 144 for Common stock. The filing lists multiple open-market sales by David Mountcastle with individual trades such as 5,361 shares for $134,030.87 on 02/26/2026 and 7,697 shares for $192,798.08 on 02/27/2026. The record also shows option-related securities listed with grant dates and exercise/Cash treatment.